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ABSTRACT 
Aims:  Severe postprandial hypoglycemia with neuroglycopenia is an increasingly recognized, 
debilitating complication of Roux-en-Y gastric bypass (RYGB) surgery.  Increased secretion of insulin 
and incretin hormones are implicated in its pathogenesis.  Histopathologic examination of pancreas has 
demonstrated increased islet size and/or nuclear diameter in post-RYGB patients who underwent 
pancreatectomy for severe refractory hypoglycemia with neuroglycopenia (RYGB+NG).  We aimed to 
determine whether β-cell proliferation or apoptosis are altered in RYGB+NG. 
Methods:  We performed an observational study to analyze markers of proliferation, apoptosis, and cell 
cycle, and transcription factor expression in pancreatic tissue from affected RYGB+NG patients (n=12), 
normoglycemic patients undergoing pancreatic surgery for benign lesions (controls, n=6, and individuals 
with hypoglycemia due to insulinoma (n=52). 
Results:  Proliferative cell nuclear antigen (PCNA) expression was increased in insulin-positive cells in 
RYGB+NG patients (4.5-fold increase, p<0.001 vs. controls) and correlated with β-cell mass.  Ki-67 
immunoreactivity was low in both RYGB+NG and controls, but did not differ between groups.  Phospho-
histone H3 levels did not differ between RYGB+NG and controls.  PCNA and Ki-67 were both 
significantly lower in both controls and RYGB+NG than insulinomas.  Markers of apoptosis and cell 
cycle (M30, p27, and p21) did not differ between groups.  PDX1 and menin exhibited similar expression 
patterns, while FOXO1 appeared to be more cytosolic in RYGB+NG. 
Conclusions: Markers of proliferation are heterogeneous in patients with severe post-RYGB 
hypoglycemia.  Increased β-cell proliferation in some individuals may contribute to increased β-cell mass 
observed in severely affected patients. 
Keywords:  islet, hypoglycemia, human, gastro-entero pancreatic factors 
Abbreviations:  roux-en-Y gastric bypass (RYGB), neuroglycopenia (NG)
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Introduction 
Bariatric surgery is increasingly performed for treatment of both obesity and type 2 diabetes (T2D).  
Randomized clinical trials comparing bariatric surgery with medical management have demonstrated that 
surgery achieves not only weight loss, but also improved glycemic control while reducing the need for 
medications [1-3].  One rare but increasingly recognized complication of Roux-en-Y gastric bypass 
(RYGB) surgery is severe hypoglycemia with neuroglycopenia [4, 5].  While severe hypoglycemia may 
occur in fewer than 1% of patients [6-8], mild, often unrecognized, hypoglycemia is more frequent [9, 10] 
and may contribute to increased appetite and weight regain after surgery [11].  More severely affected 
patients can develop profound neuroglycopenia, with falls, motor vehicle accidents, loss of consciousness, 
and seizures refractory to dietary management.  Neuroglycopenic symptoms typically appear two or more 
years after RYGB surgery, well after weight loss has stabilized.  Hypoglycemia usually occurs in the 
postprandial period and is accompanied by inappropriately high plasma insulin [12].  Higher levels of 
glucagon-like peptide-1 (GLP1) and other incretins may promote excessive insulin secretion [13, 14].  
Increased insulin-independent glucose uptake may also contribute to hypoglycemia [15].  Some patients 
initially improve with medical nutritional therapy but may require progressive pharmacologic strategies, 
including acarbose to reduce carbohydrate absorption, and somatostatin analogs, diazoxide, and/or 
calcium channel blockade to reduce insulin secretion [16].  Surgical procedures which increase gastric 
restriction [17, 18] or tube feeding into the gastric remnant [19] have been successful for some patients.  
Reversal of gastric bypass may improve hypoglycemia, but is not uniformly successful [4, 20]. 
Partial pancreatectomy was previously performed in a small number of patients with severe 
neuroglycopenia refractory to medical management, in an attempt to reduce the frequency and severity of 
hypoglycemia [4, 5]. While some patients experience initial improvements following partial 
pancreatectomy, hypoglycemia often recurs [4, 21], suggesting progressive β-cell dysregulation and 
inappropriate insulin secretion.  Pathologic examination of pancreatic tissue from severely affected 
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patients who underwent pancreatectomy reveals large and small islets, often of irregular shape and 
clustered near ducts, with nuclear atypia, similar to findings seen with nesidioblastosis unrelated to gastric 
surgery [4, 5, 22].  Insulinoma has also been reported rarely in post-bypass patients [23]; whether this is 
linked to stimulation of proliferation and clonal expansion or to increased diagnostic attention in post-
RYGB patients remains uncertain.  β-cell mass is quantitatively increased in some [24] but not all series 
[25], potentially due to small cohort sizes or heterogeneity among case or control samples. 
To determine whether cell proliferation or apoptosis are altered in pancreatic -cells from patients with 
post-RYGB hypoglycemia with neuroglycopenia (RYGB+NG), we examined pancreatic samples 
obtained from patients who had undergone partial pancreatectomy for refractory hypoglycemia.  Results 
were compared with those obtained in pancreatic samples from patients with normoglycemia undergoing 
pancreatic resection for benign mass lesions or other diseases, and from patients with hypoglycemia due 
to insulinoma. 
 
Research Design and Methods: 
Patients: Consecutive patients presenting to either Joslin Diabetes Center (n=8) or University of Texas 
Health Science Center at San Antonio (n=4) for surgical management of post-RYGB hypoglycemia 
refractory to medical management were included in this cross-sectional observational study.  Diagnosis of 
post-RYGB+NG was made on the basis of documented venous hypoglycemia with neuroglycopenia, 
inappropriately high insulin levels at the time of spontaneous hypoglycemia, and normal glucose and 
appropriately suppressed plasma insulin after an overnight fast or prolonged inpatient fast.  Sample size 
was determined by the availability of specimens from patients with post-RYGB+NG who underwent 
palliative partial pancreatectomy in an attempt to control severe hypoglycemia; this number is limited, as 
pancreatic surgery is no longer performed in our institution for this condition due to incomplete efficacy.  
Control pancreatic tissues were obtained from patients without diabetes who underwent pancreatic 
surgery for benign pancreatic mass lesions (n=6) at Brigham and Women’s Hospital or Beth Israel 
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Deaconess Medical Center.  Patients requiring surgery for malignancy were excluded.  Fifty-two sporadic 
insulinomas in patients with severe hypoglycemia treated at Haukeland University Hospital (n=7) or at 
Ospedale di Circolo (n=45) were also analyzed.  
The study was approved by the Institutional Review Board or Regional Ethics Committee at each 
institution, and performed according to the Helsinki Declaration. 
Surgical collection of samples: Partial pancreatectomy was performed for patients with severe post-
RYGB hypoglycemia after extensive hormonal evaluation, noninvasive imaging, and arteriography with 
selective calcium-stimulated insulin secretion testing to rule out insulinoma and define the anatomic site 
of dominant insulin secretion.  Routine diagnostic evaluation of pancreatic specimens was performed by 
pathologists at each institution, and detailed gross and microscopic analysis to rule out insulinoma or 
other neuroendocrine tumors was performed in all patients.  Some cases included in our study were 
previously described in clinical case series on post-RYGB hypoglycemia [4], analysis of GLP1R 
expression [24], or prior studies of insulinoma [26, 27].  Patient gender and age are provided in Table 1; 
for one control and two post-RYGB patients, only de-identified information was available.  For 
insulinomas, tumors and adjoining pancreatic parenchyma were resected at laparotomy.  Large or 
infiltrating tumors were resected using standard surgical procedures (Whipple resection, middle or distal 
pancreatectomy), whereas small (≤ 2cm) well-defined, encapsulated and superficially localized 
insulinomas were enucleated.  Insulinomas were classified according to the 2010 WHO classification of 
tumors of the digestive system [28]. 
Immunostaining protocols: Pancreas tissues were fixed in 10% buffered formalin at 4oC overnight, and 
embedded in paraffin.  Serial sections (5 μm thick) were used for all immunostainings.  After being 
microwaved for 20 minutes in 10 mM sodium citrate, sections were blocked with donkey serum (5%) and 
incubated with primary antibodies against: a) PCNA (Dako, mouse monoclonal, clone PC10, 1:400), b) 
phosphohistone H3 (Millipore, 06570), c) Ki-67 (Dako, mouse monoclonal, clone B56 or MIB1, 1:100 
dilution), d) P27 (BD, mouse monoclonal, clone 57, 1:25), e) P21 (Dako, mouse monoclonal, clone 
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SX118,  1:20), anti-caspase cleavage product of cytokeratin 18 (M30 CytoDeath, Hoffmann-LaRoche 
mouse monoclonal, clone M30, 1:100), f) PDX1 (Cell Signaling, rabbit polyclonal, 1:400), g) FoxO1 
(Cell Signaling, rabbit polyclonal, 1:50), h) Menin (Abcam, rabbit polyclonal, 1:1600), and i) insulin 
(Abcam, Guinea pig polyclonal, 1:200, or Cell Signaling, rabbit polyclonal, 1:400 or BioGenex, mouse 
monoclonal, clone AE9D6, 1:100).  Specific signals were detected using fluorescence-conjugated 
secondary antibodies (Jackson Immunoresearch, Alexa 488 or Alexa 594, 1:400).  P27, P21 and PCNA 
were detected by polymer-HRP/AP-conjugated secondary antibody (Dako), followed by color 
development with 0.03% 3,3’diaminobenzidine tetrahydrochloride (DAB) or permanent red substrate. 
For quantification of Ki-67 or PCNA positivity,  sections were co-stained with PCNA or Ki-67 and 
insulin, and then counterstained with DAPI. 
Slides were examined under AXIO Imager A2 Fluorescence/Bright Field microscope (Zeiss) and images 
were captured with the same background setting by a single observer masked to group.  Cell counting was 
conducted using Image J software (Rasband, W.S., ImageJ, U. S. National Institutes of Health, Bethesda, 
Maryland, USA, http://rsb.info.nih.gov/ij/, 1997-2009).  For each sample, 1000-2000 β-cells (insulin 
positive cells) were counted; the number also positive for PCNA, pHH3, or Ki-67 was counted and the 
percentage of insulin-positive cells was calculated [28].  The number of patients analyzed for each 
antibody is indicated in figure legends. M30 immunostainings were performed as described previously 
[29]. 
β-cell area and nuclear area:  Immunofluorescent staining for insulin was carried out by using guinea pig 
anti-insulin primary antibody (Abcam) and Alexa-conjugated secondary antibody.  Images were captured 
using Olympus BX60 fluorescence microscope under both 4x and 20x magnification for the whole 
pancreas and all of the individual islets.  Nuclear area was measured in 500 randomly selected β-cells 
from each section.  Images were analyzed using Image J software.  β-cell area was expressed as a fraction 
of the pancreas area (multiplied by 100). 
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Statistics: Student’s t-tests (2-tailed, unequal variance) or χ2 tests were used to assess between-group 
comparisons.  Linear regression was used to assess the relationship between proliferative markers and 
islet mass.  Results were considered significant if P<0.05. 
Results: 
Islet morphology and proliferation were evaluated in 12 patients with RYGB+NG and 6 normoglycemic 
controls without malignancy (Table 1).  For comparison, 52 patients with sporadic insulinoma were also 
analyzed (Supplementary Table 1). 
Morphology: Fractional β-cell area was increased in pancreas samples from RYGB+NG patients versus 
controls (5.13±0.42 vs. 1.74±0.46%, p<0.001)(Figure 1A).  Since nuclear area has been suggested to 
reflect β-cell activity [25], we measured nuclear area in 500 randomly selected β-cells from each section.  
There was no difference in nuclear diameter between RYGB+NG and controls (Figure 1B and 
Supplementary Figure 1). 
Proliferation of Insulin-Positive Cells: To determine whether increased β-cell mass in this population is 
accompanied by increased proliferation, pancreas sections were co-immunostained with insulin and either 
PCNA and Ki-67.  The percentage of cells co-immunostaining for PCNA and insulin was 4.5 fold higher 
in pancreatic tissue from RYGB+NG patients with neuroglycopenia as compared with control pancreas 
(36.5±4.1% versus 8.1±1.8%, p<0.0001, Figure 2A).  The percentage of PCNA-positive insulin-positive 
cells correlated with β-cell mass (r=0.60, p=0.02, Supplementary Figure 2). Similarly, the percentage of 
insulin-positive cells also positive for the mitosis marker phospho-histone H3 (Serine 10) was 
numerically higher in a subset of 6 patients with RYGB + NG (0.68 + 0.18) as compared with 5 controls 
(0.29 + 0.15, p=0.13, Supplementary Figure 3A/B). 
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Ki-67-positive -cells were less abundant (range 0-0.05%, Figure 2B) than PCNA-positive -cells in all 
samples.  Four of 12 samples from patients with RYGB+NG had detectable Ki-67 immunoreactivity, 
compared to only one of 6 control samples (p=0.44, Fisher’s exact test). 
PCNA and Ki-67 data were compared to values in patients with insulinoma, since both insulinoma and 
RYGB+NG are characterized by hyperinsulinemia, and increased levels of insulin or signaling through 
the insulin/IGF-1 receptors could potentially contribute to proliferation in non-neoplastic pancreas [30]. 
As predicted, tumor samples had a higher percentage of positivity for the proliferation markers PCNA 
(92.2±1.4%) and Ki-67 (0.8±0.3%) as compared with non-neoplastic islets in the same individuals and 
with both RYGB+NG and controls (Figure 2A/2B and Supplementary Figure 4).  Similarly higher 
proliferation (Ki-67) was observed in a larger independent series of insulinoma, with a mean Ki-67 index 
of 2.4±0.4% (n=45).  In islets outside of, but adjacent to, the insulinoma (at least 25 μm away from the 
tumor), the percentage of PCNA-positive insulin-positive cells was 35.0±9.0%, and the percentage of Ki-
67-positive insulin-positive cells was 0.06±0.06% (Figure 2A/2B, right column, and Supplementary 
Figure 4).  These values were lower than for the adjacent tumor, as expected, but higher than control 
samples and quantitatively similar in magnitude to RYGB+NG islets.  Percent positivity for PCNA 
correlated with percent positivity for Ki-67 across the cohort of both insulinoma and post-RYGB patients 
(r=0.34, p=0.03). 
Apoptosis: Reduced apoptosis could also contribute to increased β-cell mass.  To investigate this 
possibility, consecutive pancreatic sections were immunostained with the apoptosis marker M30 
antibody.  No significant M30 positivity was detectable in either RYGB+NG patients or controls 
(representative sections, Figure 3A).  Similarly, there were no differences in overall immunoreactivity or 
subcellular distribution for the additional apoptosis markers p27 or p21 (Figure 3B/C and 
Supplementary Figure 5).  In insulinoma samples, there were no detectable differences in p27 
immunoreactivity in comparison with surrounding non-neoplastic islets (Supplementary Figure 5A), 
p21 was 7-fold higher in tumor (p<0.01, Supplementary Figure 5B/C). 
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Transcription Factors: Pancreatic sections were immunostained for key transcription factors that regulate 
β-cell development and differentiation, including pancreatic and duodenal homeobox 1 (PDX1), forkhead 
box O1 (FOXO1), and menin.  PDX-1 expression in β-cells from RYGB+NG patients was both nuclear 
and cytoplasmic in distribution, whereas it was localized in the nucleus of control β-cells (Figure 4, top 
row).  Likewise, FoxO1 was largely excluded from the nucleus in RYGB+NG subjects; by contrast, in 
control samples the majority of insulin-positive β-cells exhibited nuclear FoxO1 expression with minimal 
cytoplasmic immunoreactivity (Figure 4, middle row).  Menin, implicated in β-cell replication and 
MEN1-linked tumorigenesis [31], was similarly expressed in the nucleus of all β-cells and non-islet cells 
in both RYGB+NG and control patients (Figure 4, lower row). 
In pancreas sections from patients with insulinoma, the transcription factors PDX1, FOXO1, and menin 
were detected in both tumor and peri-tumor islets.  Both nuclear and cytoplasmic expression of all factors 
was observed in tumor cells (Supplementary Figure 6A-C, upper panels), while expression was 
predominantly nuclear in peri-tumor islets (Supplementary Figure 6A-C, lower panels). 
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Discussion 
Hypoglycemia following RYGB performed for severe obesity is a challenging and sometimes serious 
clinical syndrome.  Increased postprandial insulin secretion, together with increased insulin-dependent 
and insulin-independent glucose disposal, may contribute to postprandial hypoglycemia [13, 14]. 
Unfortunately, severely affected patients do not fully respond to currently available therapies aimed at 
reducing insulin and incretin secretion, underscoring the need to better understand the pathophysiology of 
this syndrome.  Interestingly, hypoglycemia can also be observed following sleeve gastrectomy but rarely 
after gastric banding [32]. 
Partial pancreatectomy has previously been utilized in severely affected patients with post-bariatric 
hypoglycemia in an attempt to reduce hypoglycemia and improve patient safety.  This approach is no 
longer routinely employed due to high morbidity and poor long-term efficacy [21].  However, some 
severely affected patients have achieved reductions in hypoglycemia frequency and severity with partial 
pancreatectomy, raising the possibility that increased islet mass could contribute to the pathophysiology 
of this syndrome.  Using surgical samples from these patients, we aimed to determine whether β-cell 
mass, proliferation, and apoptosis are altered, as compared with normal pancreas tissue from surgical 
resections for benign pancreatic lesions, and compared to pathology with hypoglycemia due to 
insulinoma. 
Histologic analysis of pancreatic samples from this patient cohort revealed significant increases in 
insulin-positive cells, as compared with surgical controls.  Increased islet mass has been detected in some 
[4, 5, 24] but not all studies [25].  Whether this reflects the heterogeneity of pancreatic pathology and β-
cell mass in this syndrome, or the wide variation in β-cell mass even in healthy individuals across a 
spectrum of obesity [33], remains uncertain.  We cannot exclude a role for prior severe obesity as driver 
of increased β-cell mass in individuals with post-RYGB hypoglycemia. 
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Increases in β-cell mass in severely affected post-RYGB patients could reflect alterations in proliferation 
or apoptosis.  Markers of apoptosis, including M30, p27, and p21, were low in all patient groups, and did 
not differ between controls and post-RYGB patients with neuroglycopenia.  By contrast, PCNA was 4.5 
fold increased in insulin-positive cells from patients with RYGB+NG, as compared with normoglycemic 
patients with benign pancreatic lesions.  Similarly, phospho-histone H3 and Ki-67 expression were 
numerically higher in insulin-positive cells in neuroglycopenic patients; these values were within a range 
similar to those reported by us previously and others [34, 35], suggesting variable extent of increased 
mitoses and proliferation in this population. Additionally, expression levels of Ki-67 were low in all non-
insulinoma samples (range 0-0.095% for Ki-67).  While reasons for differences between the magnitude of 
PCNA elevation and those for the mitotic markers PHH3 and Ki-67 remain uncertain, Ki-67 has recently 
been demonstrated to be particularly susceptible to loss of immunoreactivity during processing [36].  
Alternatively, increases in PCNA may reflect not only S phase entry into the cell cycle, but also DNA 
repair synthesis after damage [37] or growth factor-stimulated protein expression [38].  Despite these 
mechanistic possibilities and differences in magnitude, PCNA and Ki-67 markers correlated across all 
samples, consistent with prior studies showing overall concordance of these markers in human pancreatic 
tissue [39].  Moreover, PCNA positivity correlated positively with β-cell area in patients with post-RYGB 
neuroglycopenia (Supplementary Figure 2). 
Rapid changes in systemic metabolism, growth factors, improved insulin sensitivity, or paracrine factors 
could contribute to increased PCNA and/or proliferation of insulin-positive cells after RYGB.  For 
example, activation of intracellular insulin signaling has been shown to increase β-cell PCNA [40], while 
infusion of transforming growth factor (TGF) or epidermal growth factor (EGF) in healthy rats increases 
PCNA expression in both pancreatic islets and ducts independent of 3H-thymidine incorporation [38].  
Animal studies demonstrate rapid changes in β-cell mass after bariatric surgery, suggesting induction of 
proliferation.  Longitudinal studies from a pig model of gastric bypass demonstrate 2-fold increases in β-
cell mass as early as three weeks postoperatively, with increased islet number, extra-islet β-cells, and 
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GLP1 receptor density, independent of weight loss [41].  Likewise, both duodenal-jejunal bypass and 
vertical sleeve gastrectomy in rodents result in increased β-cell mass 3 months postoperatively, assessed 
by positron emission tomography [42].  One potential contributor to both increased PCNA, proliferation, 
and insulin secretion in post-RYGB patients could be the incretin hormone GLP1.  While GLP1 is 
associated with β-cell proliferation in rodents, it remains unknown whether the increased endogenous 
secretion of GLP1 observed after RYGB could also contribute to β-cell proliferative responses in humans 
[30].  Indeed, levels of GLP1 are markedly increased, up to 10-fold higher after meals in post-RYGB 
While GLP1 receptors are expressed in human islets, expression is not increased in patients with post-
bariatric hypoglycemia as compared with controls [24].  Nevertheless, it remains possible that 
exceedingly high levels of GLP1 in post-bypass patients could contribute to GLP1-dependent responses.  
We acknowledge that  alterations in β-cell mass are not consistently observed in patients with post-RYGB 
hypoglycemia [25], indicating that increased proliferation and/or β-cell mass may not be absolutely 
essential for functional dysregulation of insulin secretion observed in this syndrome. 
We find localization of FOXO1 is more cytosolic in those with post-RYGB neuroglycopenia compared to 
nonsurgical controls.  Potential mediators of this pattern include increases in levels or action of growth 
factors, such as insulin or hepatocyte growth factor [43-45]. Since these localization patterns of FOXO1 
differed between insulinoma and post-RYGB hypoglycemia patients, additional factors beyond high 
circulating insulin concentrations are likely to contribute in the post-RYGB setting.  For example, 
increased expression of insulin-like growth factor-2 (IGF2) and insulin-like growth factor-1 receptor-α 
(IGF1Rα) have been reported in post-RYGB patients [22] and could also contribute to both altered 
FOXO1 regulation and islet function.  
A single case report indicated increased PDX1 expression [46] in a post-RYGB patient, as seen in rodent 
models [47]; however, PDX1 expression patterns did not differ in our series of post-RYGB hypoglycemic 
patients.  Menin was localized to the nucleus in both β-cells and ductal cells, implicating a potential 
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functional role in both cell types [31].  However, immunostaining for menin did not differ in post-bypass 
hypoglycemia patients compared to control, indicating menin is not likely to be a major contributor to the 
post-RYGB hypoglycemia syndrome. 
Parallel analysis of samples from patients with insulinoma, who have hypoglycemia due to excessive and 
autonomous insulin secretion by tumor cells, revealed the expected increases in both Ki-67 and PCNA, 
thus serving as a positive control.  Levels of Ki-67 were not as high in adjacent normal islets, consistent 
with prior data [48].  However, PCNA was also increased in adjacent normal islets, with magnitude 
similar to that of RYGB+NG islets.  These findings raise the possibility that endocrine or paracrine 
effects of excessive insulin secretion by either tumor or non-tumor mechanisms could contribute to PCNA 
positivity in β-cells. 
Both insulinoma tumor and adjacent cells showed presence of nuclear PDX1, FOXO1, and menin.  As 
noted, these patterns are distinct from those in post-RYGB neuroglycopenia, despite common increases in 
insulin levels.  Cellular phenotypes exclusive to insulinoma could be linked to transformation or 
transdifferentiation; the effects of sustained increases in insulin/IGF-1 signaling via phosphoinositide 3-
kinase (PI3K) or Akt-dependent pathways [4], the autocrine effects of local growth factors, alteration in 
regulation of cell cycle regulatory proteins [49] or additional mechanisms exclusive to tumor cells (e.g. 
increases in GLP1 receptor density) [24] will require additional investigation. 
In summary, we find the proliferation marker PCNA is increased in parallel with increased β-cell area in 
patients with post-RYGB neuroglycopenia.  Whether such alterations in pancreatic pathology are linked 
to dysregulation of postprandial insulin secretion, potentially via common upstream mechanisms, or are 
independent of each other, remains uncertain and cannot be addressed by examination of tissue pathology.  
We recognize our study is limited by sample size, heterogeneity between patients, and the inability to 
compare pre- and post-RYGB pancreatic samples from the same patient.  Moreover, these data may not 
be generalizable to the entire population of less severely affected patients with post-RYGB hypoglycemia, 
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or to those post-RYGB patients without clinically recognized hypoglycemia.  Future studies will be 
required to analyze potential transcriptional contributors to increased insulin secretion. 
More broadly, understanding processes that may lead to improved β-cell function is an area of significant 
interest given the need to find novel ways to counter progression of T2D.  Multiple studies provide 
convincing evidence that rodent β-cells can be stimulated to proliferate, leading to increased functional β-
cell mass.  A series of emerging reports support this possibility in human β-cells [34, 35, 50-52]. 
Whether the ability to proliferate can be harnessed to modulate the overall functional β-cell mass for 
therapeutic purposes warrants further investigation and should continue to spur efforts to identify both 
systemic and paracrine mediators of islet mass and functional capacity. 
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TABLE 1 
Gender Age (years) 
BMI at 
RYGB 
BMI at 
Pancreatic 
Surgery 
Pathology 
CONTROLS (no RYGB) 
F 28 - 18 Microcystic serous cystadenoma 
F 38 - 25.1 Leiomyoma, normal pancreas 
n/a n/a - n/a Localized pancreatic tumor 
M 69 - n/a Serous cystadenoma 
M 65 - n/a Intraductal papillary mucinous adenoma 
F 43 -  n/a Ampullary adenoma, normal pancreas 
POST-RYGB NEUROGLYCOPENIC HYPOGLYCEMIA 
M 46 40.6 23.1 Islet hyperplasia 
F 42 n/a 30 Islet hyperplasia 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
21 
F 35 42.3 37.5 Islet hyperplasia 
F 37 n/a n/a Islet hyperplasia 
F 29 46.8 26.3 Islet hyperplasia 
F 33 40 25.8 Islet hyperplasia 
F 49 43.5 29.7 Islet hyperplasia 
F 69 n/a n/a Islet hyperplasia 
n/a n/a n/a n/a Islet hyperplasia 
F 54 n/a n/a Islet hyperplasia 
F 36 n/a n/a Islet hyperplasia 
n/a n/a n/a n/a Islet hyperplasia 
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TABLE AND FIGURE LEGENDS 
Table 1.  Characteristics of patients from whom pancreatic samples were obtained at surgery.  n/a, data 
not available. 
Figure 1.  A. Area (% of total pancreas area) and B. nuclear area (μm) in insulin-positive cells in controls 
(n=6) and patients with post-RYGB hypoglycemia (RYGB+NG, n=9).  Nuclear size was assessed in 500 
cells per patient. 
Figure 2.  Representative images (left) and quantification (right) for (A) PCNA and (B) Ki-67 staining, 
expressed as percentage of insulin-positive cells in samples from controls (n=6), patients with 
RYGB+NG  (n=11 for PCNA, 12 for Ki-67).  These data are compared with neoplastic cells from patients 
with insulinoma (n=7), and with surrounding non-neoplastic islets.  1000-2000 β-cells were counted for 
each patient.  *** indicates p<0.0001. 
Figure 3.  Representative images for the apoptosis markers and related proteins (A) M30, (B) p27 and (C) 
p21.  1000-2000 β-cells were counted. 
Figure 4.  Representative images of immunostaining for the transcription factors PDX1, FOXO1, and 
menin (green), and insulin (red). 
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Supplementary Table and Figure Legends 
Supplementary Table 1.   Characteristics of patients with insulinoma. 
Supplementary Figure 1.  Representative images of β-cells stained with DAPI (blue) and for insulin 
(red).  
Supplementary Figure 2.  Correlation between % PCNA-positive insulin-positive cells and β-cell mass 
(% of area).  Red symbols denote RYGB+NG, while black symbols indicate controls.  Spearman r=0.68, 
p<0.01. 
Supplementary Figure 3.  A.  Representative images of proliferation marker phospho-histone H3 in 
pancreas sections, expressed as percentage of insulin-positive cells in samples from controls (n=5) and 
patients with RYGB+NG  (n=6).   Arrows indicate cells selected for display in higher-magnification inset.  
B. Quantification of phosph-histone H3 positive, insulin-positive cells. 
Supplementary Figure 4.  Representative images of proliferation markers (A) PCNA and (B) Ki-67 in 
pancreas sections from 7 patients with insulinoma (INS1-7).  Upper panels depict normal pancreas 
(adjacent to tumor) within the surgical specimen, while lower panels shows insulinoma tumor tissue.   
Arrows indicate cells selected for display in higher-magnification inset.  
Supplementary Figure 5.  Representative images of apoptosis markers (A) p27 and (B) p21 in pancreas 
sections from 7 patients with insulinoma (INS1-7).  Upper panels depict normal pancreas (adjacent to 
tumor) within the surgical specimen, while lower panels shows insulinoma tumor tissue. Arrows indicate 
insulinoma and adjacent non-neoplastic insulin-positive cells. *indicates p=0.004. 
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cells selected for display in higher-magnification inset.   (C) Quantification of percentage of p21+ cells in
24 
Supplementary Figure 6. Representative immunostaining images for the transcription factors (A) PDX1, 
(B) FOXO1, and (C) menin (green) and insulin (red) in normal and tumor tissue from patients with 
insulinoma. Arrows indicate cells selected for display in higher-magnification inset.  
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
Figure 1.  
0
2
4
6
8
10
CONTROL RYGB
In
s
u
li
n
-P
o
s
it
iv
e
 C
e
ll
 A
re
a
(%
 o
f 
to
ta
l 
p
a
n
c
re
a
s
 a
re
a
)
***
In
s
u
li
n
-P
o
s
it
iv
e
 C
e
ll
 
N
u
c
le
a
r 
A
re
a
(µ
2
)
B.
0
10
20
30
40
50
CON RYGB 
A.
Figure 1
A.  PCNA 
Control
Post-RYGB
%
 P
C
N
A
 P
o
s
it
iv
e
 I
n
s
u
li
n
 P
o
s
it
iv
e
 C
e
ll
s
CONTROL RYGB
+ NG 
***
INSULINOMA PERI-
TUMOR
***
Control
Post-RYGB
%
 K
i6
7
 P
o
s
it
iv
e
 I
n
s
u
li
n
-P
o
s
it
iv
e
 C
e
ll
s
***
B.  Ki67
CONTROL RYGB
+ NG 
INSULINOMA PERI-
TUMOR
Figure 2
Figure 3. 
A.  M30 B. p27
Control
Post-RYGB
Post-RYGB
C. p21
Control
Control
Post-RYGB
Figure 3
PDX1
Insulin
Menin
Insulin
Figure 4.  Control Post-RYGB
FoxO1
Insulin
Figure 4
Post-RYGB  
Insulin 
DAPI 
Control 
Supplementary Figure 1.   
r=0.68 
p<0.01 
Supplementary Figure 2.   
●  Control 
■  RYGB+NG 
Supplementary Figure 3.   
Post-RYGB  
Control 
0.0 
0.2 
0.4 
0.6 
0.8 
1.0 
A.  Phospho-Histone H3 and Insulin Co-Immunostaining B.  Quantification 
CONTROL RYGB 
+ NG  
%
 P
H
H
3 
Po
si
tiv
e 
In
su
lin
 P
os
iti
ve
 C
el
ls
 
Supplementary Figure 4.   
INS4 INS5 INS6 INS7 
A. PCNA 
INS1 
Tumor 
Tissue 
Normal 
Tissue 
INS2 INS3 
B. Ki67 
Normal 
Tissue 
Tumor 
Tissue 
INS4 INS5 INS6 INS7 
Supplementary Figure 5.   
Tumor 
Tissue 
Normal 
Tissue 
Normal 
Tissue 
Tumor 
Tissue 
A. P27 
B. P21 
Tumor 
Tissue 
Normal 
Tissue 
Tumor 
Tissue 
Normal 
Tissue 
INS1 INS2 INS3 
Supplementary Figure 5.   
C. 
Peri-
Tumor 
Insulinoma 
** 
0 
20 
40 
60 
%
 p
21
+ 
B
et
a 
C
el
ls
 o
r T
um
or
 C
el
ls
 
A. PDX1 
B. FoxO1 
Supplementary Figure 6.   
Tumor 
Tissue 
Normal 
Tissue 
Tumor 
Tissue 
Normal 
Tissue 
INS1 INS2 INS3 INS4 INS5 INS6 INS7 
C. Menin 
Tumor 
Tissue 
Normal 
Tissue 
Not  
Available 
Supplementary Figure 6 (continued).   
INS1 INS2 INS3 INS4 INS5 INS6 INS7 
Supplementary Table 1 
 
 
 
 
INSULINOMA SAMPLES 
Sex Age Ki-67 (%) 
Series 1 (Norway) 
3M , 4F 60.3 + 6.3 0.82 + 0.29% 
Series 2 (Italy) 
23 M, 22 F 47.9 + 2.6 2.44 + 0.42% 
